RTP Mobile Logo


Module 1: Biologic Rationale for and Current Research Database with Immune Checkpoint Inhibition in Gynecologic Cancers

Track 1: Microsatellite instability (MSI) testing algorithms for patients with gynecologic cancers
Track 2: Sequencing of immune checkpoint inhibitors for patients with gynecologic cancers
Track 3: Case (Dr Powell): A woman in her 60s attains a complete response after treatment with pembrolizumab and an IDO inhibitor on a clinical trial for recurrent MSI-high endometrial cancer
Track 4: Integration of checkpoint inhibitors into the treatment algorithm for cervical cancer
Track 5: Biologic rationale for the use of checkpoint inhibitors for cervical cancer
Track 6: Case (Dr Westin): A woman in her 40s with recurrent squamous cell carcinoma of the cervix that was PD-L1-positive experiences a durable response to pembrolizumab
Track 7: Role of immune checkpoint inhibitors in the treatment of gynecologic cancers
Track 8: Duration of response to checkpoint inhibitors
Track 9: GARNET: A Phase I study investigating the efficacy of the novel anti-PD-1 antibody TSR-042 in patients with previously treated MSI-high endometrial cancer

Module 2: Targeting Folate Receptor Alpha in Patients with Gynecologic Cancers

Track 10: Biologic rationale for targeting the folate receptor alpha in patients with gynecologic cancers
Track 11: Efficacy and tolerability of the antibody-drug conjugate mirvetuximab soravtansine in patients with ovarian cancer
Track 12: Ongoing investigation of mirvetuximab soravtansine for patients with ovarian cancer
Track 13: Case (Dr Birrer): A woman in her 60s with Stage IIIC ovarian cancer experiences disease progression on multiple lines of therapy and then attains a partial response after receiving mirvetuximab soravtansine on the FORWARD I trial

Module 3: Other Novel Agents and Strategies Under Investigation for Cervical, Endometrial and Ovarian Cancer

Track 14: Case (Dr Westin): A woman in her 50s with Stage IV squamous cell carcinoma of the cervix receives the novel anti-tissue factor antibody-drug conjugate tisotumab vedotin on a clinical trial after experiencing disease progression on chemotherapy
Track 15: Case (Dr O’Malley): A woman in her 60s with recurrent ovarian cancer receives mirvetuximab soravtansine and carboplatin/bevacizumab on the FORWARD II trial
Track 16: Mechanism of action and efficacy of axalimogene filolisbac, a novel Listeria-based immunotherapy, in patients with high-risk advanced cervical cancer
Track 17: Molecular profiling for patients with gynecologic cancers

Module 4: Ongoing Trials Examining the Role of Anti-PD-1/PD-L1 Antibody Combination Strategies

Track 18: Dose interruption or discontinuation due to immune-related adverse events with checkpoint inhibitors
Track 19: Correlation between autoimmune toxicity and response with checkpoint inhibitors
Track 20: Effect of the gut microbiome on activity of anti-PD-1/PD-L1 antibodies
Track 21: Case (Dr Powell): A woman in her 60s with Stage IV uterine papillary serous carcinoma experiences a good clinical response to cabozantinib and nivolumab on a clinical trial
Track 22: Incidence of pseudoprogression and accelerated disease progression with checkpoint inhibitors
Track 23: Case (Dr Birrer): A woman in her 60s with MSI-high recurrent endometrial cancer and an intermediate tumor mutation burden attains a complete response with nivolumab
Track 24: Activity and tolerability of lenvatinib with pembrolizumab in patients with advanced recurrent endometrial cancer
Michael J Birrer, MD, PhD
O’Neal Comprehensive Cancer Center
Professor of Medicine/
Hematology and Oncology
Evalina B Spencer
Chair in Oncology
The University of Alabama
at Birmingham
Birmingham, Alabama
David M O’Malley, MD
Medical Director
Gynecologic Oncology
Director, Clinical Research
Gynecologic Oncology
Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and
The James Cancer Center
Columbus, Ohio

Matthew A Powell, MD
Professor and Chief
Division of Gynecologic Oncology
Washington University
School of Medicine
St Louis, Missouri

Shannon N Westin, MD, MPH
Associate Professor
Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Neil Love, MD
Research To Practice
Miami, Florida